As enhancing Sirt1 could counteract the negative effects of increased levels of Lingo-1, which has been shown to be aberrant in ET, and effects of Res and VitD3 involve Sirt1, we wished to examine whether a pharmacological combination of Res-VitD3 could alter levels of Sirt1 and Lingo-1, induce neuroprotection, and improve ET-associated behaviors. This evidence concerns the gene SIRT1 and essential thrombocythemia.